{
  "abstract": "Background Newly diagnosed glioblastoma (ndGBM) remains one of the most challenging malignancies to treat. Since the majority of patients experience tumor recurrence (rGBM) after first-line therapy, advancements in both initial and salvage treatments are essential.Objective We report our single-center experience on the feasibility and safety of superselective intra-arterial cerebral infusion (SIACI) with bevacizumab or cetuximab after osmotic blood–brain barrier disruption (oBBBd).Methods Partial results of three distinct trials (anonymized for blinded review) were analyzed. All patients were histopathologically confirmed to have either ndGBM or previously diagnosed ndGBM that progressed to rGBM despite standard therapy and had aKarnofsky Performance Status (KPS)≥70. All patients were admitted on the same day of the surgery, and the intervention followed similar steps in all included patients. Under general anesthesia, after oBBBd with mannitol, patients received SIACI.Results Between October 2014 and March 2024, 70 patients with a mean age of 56.2±12.4 years (range: 19–78) underwent successful treatment, encompassing 139 SIACIs and 246 infusions. All planned SIACIs were completed successfully. Forty-one patients with rGBM received bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SIACI. In 133 of 139 SIACIs (95.7%), patients were discharged home with a length of stay of 1 day. The incidence of patients who experienced procedure-related and drug-related adverse events was 11.4% and 8.6%, respectively. No procedure-related deaths occurred.Conclusion In our single-center experience, comprising the largest cohort of bevacizumab or cetuximab SIACI treatment for rGBM and ndGBM, this promising and cutting-edge intervention is highly feasible and safe.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Christian Ferreira"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Marcio Yuri Ferreira"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Faith Singh"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Tamika Wong"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Sanskruti Bokil"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Sara Massimo"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Julianna Cavallaro"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Olivia Albers"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Randy D’Amico"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "David Langer"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "John Boockvar"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA"
      ],
      "name": "Yafell Serulle"
    }
  ],
  "title": "Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood–brain barrier disruption in newly diagnosed or recurrent glioblastoma: technical insights and clinical outcomes from a single-center experience",
  "uid": "f87ebb1d-51d0-5e23-9512-567d9f4ebfe4"
}